Statins: in the beginning

Since the first human trial of a hydroxymethylglutaryl-coenzyme A (HMG CoA) reductase inhibitor in 1978, the growth in importance of this drug class, both financially and medically, has been staggering. The aim of this paper is to summarise how this drug class was developed, highlighting the role of...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of the Royal College of Physicians of Edinburgh Vol. 39; no. 4; pp. 362 - 364
Main Authors Lyons, K S, Harbinson, M
Format Journal Article
LanguageEnglish
Published Scotland 01.12.2009
Subjects
Anticholesteremic Agents - history
Endo
History of medicine and histology
History, 20th Century
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - history
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Japan
Lovastatin - analogs & derivatives
Lovastatin - history
Japan
Online AccessGet full text

Cover

More Information
Summary:Since the first human trial of a hydroxymethylglutaryl-coenzyme A (HMG CoA) reductase inhibitor in 1978, the growth in importance of this drug class, both financially and medically, has been staggering. The aim of this paper is to summarise how this drug class was developed, highlighting the role ofAkira Endo.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Biography-3
content type line 23
ISSN:1478-2715
DOI:10.4997/JRCPE.2009.425